Eli Lilly’s experimental drug lowers risk of heart disease by 94%: study – New York Post November 13, 2023
FDA Approves Lilly’s Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company – Investors | Eli Lilly and Company October 26, 2023
Lilly’s next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz – FierceBiotech June 27, 2023